Back to News
Market Impact: 0.12
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2%
Source: globenewswire.com
Healthcare & BiotechTechnology & Innovation
SNS Insider projects the radioligand therapy market will expand from $2.98 billion in 2025 to $15.85 billion by 2035, implying an 18% CAGR. The forecast signals strong long-term growth potential for radiopharmaceutical and targeted cancer-therapy markets, though it is third-party market research rather than company-specific operating news.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- SpaceX in talks over 80,000 cell sites to build new wireless network
- The mobile ambitions of SpaceX see telecom stocks get hit again. What the latest developments mean.
- Zymeworks licenses cancer drug candidate ZW209 to Roche for $55m
- Trelleborg Q3 adjusted core profit up 16% on aerospace, semiconductor demand
- IDEAYA reports IDE849 trial data in lung cancer, neuroendocrine tumors
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- The $4.7 Trillion Bet: When Does AI Capex Become AI Revenue?
- Equity Research Automation Statistics: A 2026 Evidence Check